Seeking Alpha
12 Jul 2026, 17:21 UTC · 6h ago
Silence Therapeutics: PV Data Could Wake The Stock (Initiating Buy)
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
12 Jul 2026, 17:21 UTC · 6h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Silence Therapeutics (SLN) expects a pivotal Phase 2 readout for its polycythemia vera candidate, divesiran, in August 2026. — This is a binary clinical catalyst that will either significantly validate or invalidate the company's primary asset.
+0.80Phase 1 SANRECO data for divesiran showed promising symptom improvement and a reduction in phlebotomy. — Positive early-stage data increases the probability of Phase 2 success, though it is not yet definitive.
+0.40Silence Therapeutics utilizes a GOLD GalNAc-siRNA platform intended to allow for less frequent dosing compared to competitors like Rusfertide. — A competitive dosing advantage would increase the potential market share and commercial value of the drug if approved.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
The company faces significant clinical, financial, and competitive risks. — High risk of clinical failure or capital exhaustion is a standard headwind for speculative biotech valuations.
-0.30Which stocks this story touches
The analyst initiated a speculative Buy rating based on promising Phase 1 data and upcoming Phase 2 catalysts for divesiran.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
2h ago
